---
title: "Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286559285.md"
description: "Sensei Biotherapeutics reported a Q1 2026 net loss of $170.2 million, or $131.45 per share, due to one-time charges from the Faeth acquisition. The company has $202.8 million in cash and equivalents. R&D expenses rose to $17.957 million, while G&A expenses reached $19.713 million. The company has advanced its lead program, PIKTOR, into a Phase 1b/2 trial for breast cancer and expects Phase 2 data for endometrial cancer in late 2026."
datetime: "2026-05-15T11:43:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286559285.md)
  - [en](https://longbridge.com/en/news/286559285.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286559285.md)
---

# Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position

Sensei Biotherapeutics reported a net loss of $170.2 million, or $131.45 per share, for the quarter ended March 31, 2026, reflecting one-time acquired IPR&D charges related to the Faeth transaction. The company held $202.8 million in cash, cash equivalents and marketable securities as of March 31, 2026, after completing the Faeth acquisition and a $200 million private placement. Sensei said it has advanced PIKTOR into a Phase 1b/2 breast cancer trial and expects topline Phase 2 endometrial cancer data in the second half of 2026.

**Financial Highlights**

-   Net loss: $170.2 million for Q1 2026, or $131.45 per basic and diluted share.
-   R&D expenses: $17.957 million for Q1 2026 (compared with $3.725 million in Q1 2025).
-   G&A expenses: $19.713 million for Q1 2026 (compared with $3.549 million in Q1 2025).
-   Acquired in-process R&D expense: $132.957 million recorded in Q1 2026 related to the Faeth acquisition.
-   Cash, cash equivalents and marketable securities: $202.8 million as of March 31, 2026 (vs. $21.2 million as of December 31, 2025).

**Business Highlights**

-   Completed acquisition of Faeth Therapeutics and concurrent $200 million private placement to fund development of acquired programs.
-   PIKTOR (combination of serabelisib and sapanisertib), now the lead program, is an all-oral multi-node PI3K-alpha / mTORC1/2 inhibitor advanced through the Faeth transaction.
-   First patient dosed in April 2026 in the Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer (Study FTH-PIK-101); interim data expected in 2027.
-   Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) is on track to report topline data in the second half of 2026.
-   Continuing Phase 1/2 trial of solnerstotug (VISTA inhibitor) in patients with advanced solid tumors.

Original SEC Filing: Sensei Biotherapeutics, Inc. \[ SNSE \] - 8-K - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SNSE.US](https://longbridge.com/en/quote/SNSE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)
- [Immix Biopharma Announces 95% Complete Response Rate In Interim Update From Relapsed/Refractory AL Amyloidosis Clinical Trial NEXICART-2](https://longbridge.com/en/news/287200923.md)